Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

SUPPLEMENTAL ANNOUNCEMENT
PLACING OF NEW SHARES UNDER THE GENERAL MANDATE

Placing Agent

邁時金融
MAXA FINANCIAL

Reference is made to the announcement (the "**Placing Announcement**") made by Immunotech Biopharm Ltd (the "**Company**") dated 28 October 2026 in relation to, among other things, the Placing. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Placing Announcement.

As disclosed in the Placing Announcement, pursuant to the Placing Agreement: (a) the Placing Price was HK$0.300 per Placing Share; and (b) if the conditions precedent to Completion are not satisfied on or prior to the last day of the Placing Period (defined as the period from the execution of the Placing Agreement up to 12 December 2026, being the date falling 45 days after the date of the Placing Agreement), the Placing Agreement shall terminate and none of the parties to the Placing Agreement shall have any claim against the other for any costs or losses (save for any prior breaches of the Placing Agreement).

First Supplemental Agreement

The Board hereby announces that on 18 November 2026 (after trading hours), the Company and the Placing Agent entered into a supplemental agreement to the Placing Agreement (the "**First Supplemental Agreement**"), pursuant to which:

(a) the definition of "Placing Period" was amended as the period from the execution of the Placing Agreement up to 18 November 2026, being the date falling 21 days after the date of the Placing Agreement; and

(b) all other terms of the Placing Agreement (including without limitation the Placing Price and the number of Placing Shares) shall remain unchanged and in full force and effect.

Second Supplemental Agreement

The Board hereby announces that on 18 November 2026 (after trading hours) (the "**Supplemental Agreement Date**") and subsequent to the Company's entry into the First Supplemental Agreement, the Company and the Placing Agent entered into a second supplemental agreement to the Placing Agreement (the "**Second Supplemental Agreement**"), pursuant to which:

(A) the definition of "Placing Period" was amended as the period from the execution of the Placing Agreement up to 9 December 2026, being the date falling 42 days after the date of the Placing Agreement; and

(B) all other terms of the Placing Agreement (including without limitation the Placing Price and the number of Placing Shares) shall remain unchanged and in full force and effect.

The Placing Price

The minimum Placing Price of HK$0.300 per Share represents:

(i) a discount of approximately 11.76% to the closing price of HK$0.340 per Share as quoted on the Stock Exchange on the Supplemental Agreement Date; and

(ii) a discount of approximately 12.54% to the average closing price of HK$0.343 per Share as quoted on the Stock Exchange for the five (5) consecutive trading days immediately prior to the Supplemental Agreement Date.

The minimum Placing Price was determined with reference to the prevailing market price and the recent trading volume of the Shares and was negotiated on an arm's length basis between the Company and the Placing Agent. The final Placing Price will be agreed by the Company and the Placing Agent on or before the date of Completion.

Based on the closing price of the Shares of HK$0.340 per Share on the Supplemental Agreement Date, the Placing Shares have a market value of approximately HK$210.0 million.

The Directors consider that the terms of the Placing Agreement (as amended and supplemented by the First Supplemental Agreement and the Second Supplemental Agreement, including without limitation the extension of the Placing Period) are fair and reasonable, entered into on normal commercial terms after arm's length negotiations, and are in the interests of the Company and the Shareholders as a whole.

Completion of the Placing is subject to satisfaction of the conditions set out in the Placing Agreement (as amended and supplemented by the First Supplemental Agreement and the Second Supplemental Agreement) and may or may not take place. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 18 November 2026

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Mr Yang Fan, Mr Wang Ruihua, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui and Mr Cao Ran as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit, Ms Peng Sujiu and Mr Zhang Guoguang as independent non-executive Directors.